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The role of commensal microbiota in modulating host physiology is a 
rapidly emerging and expanding concept. The composition of microbiota 
is diverse and dynamic depending on diet and environmental factors. 
Changes in the composition of the microbiota have been correlated with a 
variety of pathophysiological processes, including cardiovascular disease 
and hypertension. One of the well-characterized classes of gut microbial 
metabolites are short chain fatty acids (SCFAs), which are produced by 
the breakdown of dietary fiber in the colon. Recent studies have found 
that SCFAs produced by the gut microbiota modulate host physiology by 
acting as ligands for host G-protein coupled receptors (GPCRs), including 
Gpr41, Gpr43 and Olfr78. Gpr41, also referred to as Ffar3, is a member 
of the free fatty acid receptors family (FFAR), comprising of Gpr40, 
Gpr41, Gpr43, Gpr109a and Gpr120. These receptors are activated by 
free fatty acids. Gpr41, Gpr43 and Olfr78 are activated by SCFAs, while 
Gpr109a is activated by niacin and butyrate, Gpr40 and Gpr120 are 
activated by long chain fatty acids.  
 
It has been previously reported that Olfr78 and Gpr41 differentially 
modulate blood pressure (BP) in response to acute delivery of SCFAs. 
Olfr78 is expressed in vascular smooth muscle cells and Olfr78 KO mice 
are known to be hypotensive in comparison to Olfr78 WT mice. The 
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broad goal of the work presented here was to better understand the role 
of Gpr41 in blood pressure regulation. It was hypothesized based on 
previous knowledge that Gpr41 KO mice would be hypertensive in 
comparison to Gpr41 WT mice.  
 
In the work presented, Gpr41 was localized to the vascular endothelium, 
in contrast to Olfr78, which is found in the vascular smooth muscle, 
initially by RT-PCR and substantiated by antibody staining of primary 
endothelial cells. Continuous telemetry blood pressure measurement in 3 
– month old male Gpr41 KO and WT mice determined that Gpr41 KO 
mice exhibit systolic hypertension in comparison to Gpr41 WT mice. In 
addition, Gpr41 KO mice present with elevated pulse wave velocity at 6 
months of age, but not at 3 months (time point of baseline blood 
pressure measurement). Examination of blood vessel tensile properties 
did not reveal differences in stiffness of intact aorta from Gpr41 KO and 
WT mice. Furthermore, Gpr41 KO mice do not exhibit salt sensitive 
hypertension, but interestingly, do not have an adaptive decrease in 
systolic pressure on a low salt diet, exhibited by the Gpr41 WT mice.  
 
In an attempt to understand the signaling behind SCFA – mediated 
vasodilation, it was observed that the vascular endothelium is essential 
for SCFA mediated vasodilation to occur, as vasodilation is absent in 
endothelium-denuded vessels ex vivo, consistent with a role for Gpr41 in 
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decreasing blood pressure / mediating vasodilation. The work presented 
sheds light on the novel role of Gpr41 in the endothelium in blood 
pressure regulation. SCFA receptors expressed in both the vascular 
endothelium (Gpr41) and vascular smooth muscle (Olfr78) form a 
complex network to regulate BP in response to signals produced by the 
microbiota. In the future, better understanding of these pathways has 
the potential to further our understanding of BP regulation as a whole, 
as well as to more fully uncover the unique role of the gut microbiota in 
regulating both BP and vascular tone. 
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Chemosensory receptors on the cell surface recognize a variety of signals 
and relay information into a cell, initiating an appropriate cellular 
response and enabling communication between cells, tissues and organs. 
These cell surface receptors are grouped into three families based on 
homology and function – ion channel linked receptors, enzyme linked 
receptors and G – protein coupled receptors (GPCRs). Seven trans-
membrane domain G-protein coupled receptors (GPCRs) comprise the 
largest superfamily of cell surface receptors in the human proteome[1-3]. 
GPCRs are potential therapeutic targets due to their ability to be 
modulated by pharmaceutical agents. GPCRs respond to a variety of 
stimuli ranging from light to neurotransmitters, odorants, nucleotides, 
small peptides and lipids to fatty acids, biogenic amines and 
hormones[1-3]. Many tissues express and employ GPCRs as 
chemosensors, in order to respond to metabolites and extracellular 
signals[4-9]. 
 
It has recently been reported that metabolites produced by commensal 
microbiota act as ligands for GPCRs of the host organism, allowing for an 
entirely novel paradigm of microbe-to-host GPCR signaling pathways[10-
15]. These metabolites produced by the commensal microbiota act on key 
regulatory pathways in the host, playing important roles in regulating 
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host physiology and pathophysiological processes like obesity, immune 
disorders, atherosclerosis, irritable bowel syndrome and chronic kidney 
disease[10-20]. 
  
A major class of metabolites generated as a by-product of microbial 
metabolism is short chain fatty acids, (SCFAs, namely formate, acetate, 
propionate and butyrate, pentanoate and hexanoate), produced primarily 
from the fermentation of dietary fiber[12, 21-23]. The predominant 
species of SCFA produced are acetate, butyrate and propionate, in order 
of decreasing abundance in the colon[14, 22]. Gut microbiota-derived 
SCFAs have been shown to activate a subclass of GPCRs commonly 
referred to as Free Fatty Acid Receptors (FFARs), including Gpr41, 
Gpr43[24, 25]. In addition, an olfactory receptor (subfamily of GPCRs) 
Olfr78 (human homolog hOR51E2 is also activated by SCFAs[5, 26].  
 
SCFAs mediate a significant component of microbe – to – host signaling 
by activating SCFA receptors and acting in a receptor – independent 
manner[12-14, 27-29]. SCFAs were reported to modulate host blood 
pressure via Gpr41 and Olfr78 and FFARs and Olfr78 were expressed in 
blood vessels[5, 26]. Understanding a microbe-to-host signaling pathway 
that modulates blood pressure is of fundamental importance in the 
development of hypertension therapeutics. The aim of the work presented 
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in this dissertation is to uncover the molecular mechanism underlying 
the hypotensive response to SCFAs. 
 
2.1.2 G-protein coupled receptors 
GPCRs are members of the largest gene family in the human genome. 
They are characterized by the presence of 7 – transmembrane helices, 
with an extracellular N – terminus and an intracellular C – terminus. The 
distinct name G – protein coupled receptors arises from the association 
of GPCRs with downstream signaling proteins that have GTPase 
activity[2, 30-32]. A majority of GPCRs are associated with trimeric G – 
proteins, Gα, Gβ, Gγ, while some GPCRs are known to associate with 
smaller GTPases. Gα possesses GTPase activity and aids in translation of 
ligand binding – mediated receptor activation to a cellular response. 
GPCRs serve the function of transducing an extracellular stimulus to an 
intracellular response. A wide variety of stimuli ranging from pH, light, 
ions, amino acids and nucleotides to lipids and proteins are known to 
activate GPCRs, which upon activation initiate downstream signaling 
responses in the cell aided by the heterotrimeric G proteins[1, 31]. When 
a GPCR is activated by ligand binding, it undergoes a conformational 
change and subsequently acts as a Guanine Nucleotide Exchange Factor 
for the associated Gα protein. The GPCR activates the associated Gα  
protein by exchanging the bound GDP for GTP. The activated Gα protein 
dissociates from the β and γ subunits to elicit a downstream signaling 
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response. There are different Gα proteins known, each of which initiate a 
different downstream response in the cell (Gαs, Gαi/o, Gαq/11, 
Gα12/13)[33]. The two major signal transduction pathways initiated by 
GPCRs are the cAMP pathway and phosphoinositol pathway[1, 2, 31, 33, 
34]. In addition, activated Gα subunits can signal via calcium, cGMP and 
MAPK pathway[35]. The signal transduction pathway initiated by a GPCR 
upon activation depends on the associated G   subunit. Gαs and Gαi/o 
signal via cAMP as the second messenger, synthesized by the enzyme 
adenylate cyclase. While Gαs activates adenylate cyclase, increasing 
cellular cAMP levels, Gαi/o inhibits adenylate cyclase, decreasing cellular 
cAMP levels. Gαq/11 signal via phospholipase C, with calcium and 
phosphoinositol as second messengers; Gα12/13 signal via small 
cytosolic Rho GTPases[2, 32, 34, 36]. Aside from the cellular response 
initiated by Gα proteins, G β and γ modulate ion channel function in the 
cell. 
 
2.1.3 Short chain fatty acid receptors 
A total of 4 SCFA receptors have been identified till date, Gpr41, Gpr43, 
Gpr109a and Olfr78.  
 
Gpr41 (free fatty acid receptor 3, Ffar3) 
Gpr41 and Gpr43 were identified as SCFA receptors when they were de-
orphanized together by two independent groups in 2003[37, 38]. Gpr41 
	 5	
couples to inhibitory G – protein, Gi and is best activated by propionate 
(EC50: Gpr41 = 2µM), although a variety of other SCFAs including 
formate, acetate, butyrate, and isobutyrate elicit varying degrees of 
activation[37, 38]. Importantly, the human and rat orthologs of Gpr41 
displayed similar SCFA response profiles, indicating that the signaling of 
this receptor is likely to be evolutionarily conserved[37-39]. An additional 
receptor present in humans, Gpr42, has a very high level of homology to 
Gpr41, but it is unclear whether Gpr42 is a functional gene created due 
to duplication or a pseudo gene[38-40]. 
 
Acetate, propionate and butyrate, which are stronger ligands for Gpr41, 
are produced as byproducts of microbial metabolism. Gpr41 is expressed 
in a variety of tissues and cell types including the colon, kidneys, 
sympathetic nervous system and blood vessels, where they respond to 
microbiota-generated SCFAs to mediate physiological responses of the 
host[10, 37, 38, 41-45]. In the conventional state, Gpr41 KO mice weigh 
less and gain weight at a slower rate compared to their Gpr41 WT 
littermates; furthermore, the differences in weight gain are dependent on 
gut microbiota (as illustrated by the lack of weight differences between 
genotypes in germ-free animals)[10]. On the cellular level, other studies 
have shown that Gpr41 inhibits cell proliferation and induces apoptosis 
via the activation of p53 and MAPK[46]. Furthermore, Gpr41 is expressed 
in vasculature and plays a role in regulating blood pressure in response 
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and immune cells including lymphocytes, neutrophils, monocytes and 
peripheral blood mononuclear cells (PBMC)[45, 47]. Functionally, Gpr43 
has been shown to regulate host inflammatory responses in response to 
microbial SCFAs. SCFAs have been shown to activate cytokines and 
chemokines both in cultured intestinal epithelial cells and in mice via the 
activation of Gpr43, as the response was absent in cells from Gpr43-/- 
mice. In addition, Gpr43-/- mice have extensive dysregulation of 
inflammatory responses, showing excessive inflammation in models of 
colitis, arthritis and asthma[45, 47-49].  
 
Gpr109a 
Gpr109A was initially identified as a receptor for niacin[50], and 
subsequently was also found to respond to beta-D-hydroxybutryate as 
well as butyrate[51]. Interestingly, this receptor does not respond to 
acetate or propionate, but has an EC50 for butyrate around ~1mM. 
Gpr109A has been localized to epithelial cells in the colon, where it’s 
level of expression is suppressed in the absence of commensal 
microbiota[50, 52].  
 
Olfactory receptor 78 (Olfr78) 
Olfactory Receptor 78 (Olfr78) is a chemosensory receptor, expressed in 
non-sensory tissues outside the olfactory epithelium[5, 26]. Olfr78 
responds to acetate and propionate (EC50 2.35mM and 920 µM, 
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respectively), but does not respond to butyrate (in contrast, Gpr109A 
responds only to butyrate). Importantly, the human ortholog of Olfr78, 
OR51E2 also responds to SCFAs, indicating that the function of this 
receptor is conserved through the course of evolution. Olfr78 localizes to 
the kidney, blood vessels, autonomic neurons and the olfactory 
epithelium. In the kidney, it is expressed in the afferent arteriole and in 
vascular smooth muscle cells in resistance blood vessels. Both of these 
cell types are important in blood pressure regulation. 
 
2.1.4 Hypertension 
Blood pressure (BP) is the pressure developed by circulating blood 
pressing against the walls of blood vessels. The term “blood pressure” 
commonly refers to arterial pressure and is measured in mmHg. BP is 
expressed in two values, the systolic pressure (higher pressure developed 
during contraction of the left ventricle to deliver blood to the aorta) and 
diastolic pressure (lower pressure observed when the left ventricle is 
relaxed and being filled with blood). Blood pressure of a healthy adult at 
rest falls within 100 - 140 mmHg systolic and 60 - 90 mmHg diastolic.  
 
Hypertension is defined as a condition wherein the systolic / diastolic 
pressure of an individual is persistently greater than 140 / 90 mmHg or 
when the BP is the normotensive range only upon administration of anti-
hypertensive medication[53-55]. Hypertension is a major, worldwide 
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health problem owing to its high prevalence and association with 
increased morbidity and mortality as a result of cardiovascular 
complications. Approximately 7.1 million deaths per year can be directly 
attributed to poor control of blood pressure. An estimated 29% of the 
adult US population is hypertensive and an equivalent percentage suffers 
from prehypertension; evidence shows that individuals with 
prehypertension are at particular risk of developing overt 
hypertension[53, 54].  
 
Hypertension is classified as primary or essential hypertension and 
secondary hypertension. 90 – 95% of cases have primary hypertension, 
usually due to a combination of nonspecific lifestyle, genetic or unknown 
factors, while the remaining 5 -10% of cases have attributable causes 
leading to increased blood pressure like narrowing of arteries, chronic 
kidney disease or endocrine disorders [56, 57]. Essential hypertension is 
a complex trait resulting from the interaction of multiple genes and 
environmental factors. 35 genetic loci that affect blood pressure have 
been identified by GWAS and several genetic variants that have effects on 
blood pressure have been identified[58-60]. Blood pressure is the product 
of vascular resistance and cardiac output. In people with essential 
hypertension, an increase in total peripheral vascular resistance is 
observed, which results in increased arterial blood pressure. Precise 
reasons for the increase in vascular resistance are unknown, it is 
	 10	
presumed that renal dysfunction leading to disruption of salt – water 
balance, increase[61, 62] of sympathetic output or endothelial 
dysfunction may lead to an increase in vascular resistance in 
hypertension[63-65].   
 
In addition to the contribution of renal dysfunction, vascular resistance 
and sympathetic nervous system, the immune system, also contributes 
to the development and manifestation of hypertension[66]. Animals with 
hypertension exhibit an increase in inflammatory cells in the blood and 
bone marrow resulting in immune infiltration of kidneys and other 
tissues, leading to end–stage organ damage[67]. This inflammatory 
response also leads to the production of cytokines that increase sodium 
retention in the kidney and vasoconstriction, resulting in increased 
peripheral resistance, which further augments the hypertensive 
condition[67, 68].  
 
Management of hypertension is of utmost importance because increased 
arterial pressure over a prolonged period of time results in a host of 
cardiovascular and renal complications, and increases the risk of stroke. 
A combination of antihypertensive medication and lifestyle modifications 
are prescribed to reduce blood pressure to 140 – 160mmHg systolic and 
90 – 100 mmHg diastolic pressure[69]. Pharmacological intervention for 
hypertension is carried out using one or a combination of thiazide 
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diuretics, calcium channel blockers, angiotensin – I converting enzyme 
(ACE) inhibitors or alpha / beta-adrenergic receptor antagonists[61, 62]. 
 
Advances in the diagnosis and treatment of hypertension have had a 
major impact on management of this chronic disease. However, despite 
these advances, it is estimated that 1.56 billion people will suffer from 
hypertension by 2025[53]. Further methods are therefore needed to 
manage hypertension and its associated risks. The development of such 
therapeutic interventions will be facilitated by an increased 
understanding of the pathogenic mechanisms underlying this condition. 
  
2.1.5 Microbiome and microbe – to – host signaling 
The population of commensal microbes that reside mainly in the gut and 
several other sites in the body are collectively referred to as the 
microbiota and the collective genome of these microbes is called the 
“microbiome”. There has been an explosion of literature on microbiota 
and their effect on host health and disease in the recent few years. 
Microbiota play an integral role in modulating host physiology, immune 
system and pathophysiology. Metabolites produced by gut microbiota act 
as ligands for host receptors and GPCRs [70, 71], allowing for an entirely 
novel paradigm of microbe-to-host GPCR signaling pathways. These 
metabolites produced by the gut microbiota act on key regulatory 
pathways in the host, playing important roles in regulating host 
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physiology and pathophysiological processes like immune disorders[72], 
atherosclerosis[73], irritable bowel syndrome[74, 75] and chronic kidney 
disease[76, 77]. Recent studies suggest that development and onset of 
cardiovascular and metabolic diseases are influenced by microbial 
composition and metabolites[15, 78-80].  
 
The composition of microbiota of an individual, referred to as the 
“enterotype”, is dynamic and constantly changing due to changes in diet 
and environment[81]. Recent data suggests that a disruptive change in 
microbial composition to a pathological state, "dysbiosis"[16], is related 
to chronic inflammatory diseases like asthma and inflammatory bowel 
disease[15, 47, 82-84]. Balance of the abundance of different species in 
the gut is key to maintaining homeostasis in the intestinal environment 
and normal physiology of the host. An individual's microbiota is diverse 
and comprises of many species, but 4 phyla are most abundant - 
firmicutes, actinobacteria, proteobacteria, bacterioidetes. A ratio of the 
relative abundance of two microbial species Firmicutes and Bacteriodetes 
(F/B ratio) is potentially used as a biomarker for pathological 
conditions[85-87].   
 
Dysbiosis was observed in a small cohort of hypertensive humans with a 
marked increase in the F/B ratio, treatment with antibiotic minocycline 
to alter the microbiota resulted in a decrease in BP[79, 88]. An 
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independent study reported differences in microbiota composition 
between salt –sensitive and salt – resistant rats[20]. Decreased systolic 
and diastolic BP have been reported with a regular consumption of 
probiotics and dietary fiber in population studies[89, 90]. Furthermore, 
the dysbiosis observed in hypertensive individuals resulted in a decrease 
in SCFA production by the microbiota[87, 91], indicating that microbiota 
affect host BP via SCFAs and that in a state of dysbiosis, microbiota 
could contribute to the manifestation of hypertension by modulating the 
immune system.  
 
Understanding the basis of microbiota and SCFA – mediated BP 
regulation could enable development of alternate dietary strategies for 
management of hypertension that could be combined with existing 





Aim 1: Localization and signaling of Gpr41 
(a) To determine the localization of Gpr41 and identify the cell – type 
in which Gpr41 is localized in a blood vessel 
(b) To elucidate the signaling mechanism of Gpr41  
a. at the cellular level by studying the signaling of Gpr41 in 
endothelial cells at the tissue level  
b. in blood vessels ex vivo; by examining the effect of SCFAs on 
vascular resistance of tail resistance arteries from Gpr41 KO 
and Gpr41 WT mice. 
 
Aim 2: Role of Gpr41 in blood pressure regulation 
(a) To study the role of Gpr41 in blood pressure regulation – baseline 
blood pressure in Gpr41 WT and KO animals 
(b) To explore the effect of chronic SCFAs administration on blood 
pressure in Gpr41 KO and WT mice  
(c) To examine the effect of high salt and low salt diets on blood 





Modulation of blood pressure and vascular resistance by microbial 
metabolites is a novel pathway that is not understood clearly. Most 
digestion and nutrient assimilation occurs in the small intestine, 
whereas, breakdown of dietary fiber occurs in the colon. Significant 
quantities of SCFAs are produced following a meal, resulting in 
vasodilation, which may facilitate efficient absorption of nutrients into 
the circulation. An increase in plasma SCFA after a meal causes a 
transient postprandial hypotension documented especially in elderly 
populations[92]. 
 
There are two SCFA receptors (Olfr78 and Gpr41) that signal in response 
to SCFAs in order to modulate blood pressure. The primary response to 
an increase in plasma SCFAs in wild-type mice is a decrease in blood 
pressure, which is driven by Gpr41[5, 26]. This hypotensive response, 
however, is opposed by the actions of Olfr78, which acts to increase 
blood pressure upon activation by SCFAs[5, 26]. It is hypothesized that 
commensal microbiota play an integral role in maintaining blood 
pressure by producing SCFA metabolites that act predominantly via 
Gpr41 to modulate blood pressure. The purpose of having two receptors 
for the same ligand work in opposing directions is related to the fact that 
Gpr41 and Olfr78 have very different EC50s for SCFAs (Propionate: 
Gpr41, EC50 274 µM1; Olfr78, EC50 0.9 mM)[26, 37, 38]. Therefore, 
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under basal conditions (in which plasma SCFAs are 0.1-10mM) one 
would expect Gpr41 but not Olfr78 to be tonically active. When plasma 
SCFAs begin to rise (i.e., following a meal), Gpr41 would be further 
activated and therefore would further lower blood pressure. However, 
once SCFA concentrations are elevated such that Olfr78 is activated as 
well, activation of Olfr78 would act as a ‘brake’ on the hypotensive 
pathway, acting as a failsafe against dangerous levels of hypotension 
when SCFA concentrations are high. 
 
Detection of environmental cues by GPCRs has gained significant 
attention recently. Studies have shown that complex signaling networks 
enable cells and tissues to respond to external signals, altering 
physiological processes. Microbe-to-host signaling is a recent and 
upcoming area of investigation, as the ability of commensal organisms to 
alter host physiology reveals an entirely new layer of physiological 
regulation. The results presented indicate a novel source (gut microbiota) 
of molecules, which can affect blood pressure regulation. The 
hypotensive effects observed with the elevation of SCFAs in plasma imply 
that, in the future, it is possible that manipulation of gut microbiota 
could be an alternative therapy for hypertension. 
	 18	




we previously showed that 3 SCFA receptors, Gpr41, Gpr43 and Olfr78 
are expressed in major blood vessels (aorta, renal artery and iliac artery). 
In this section Gpr41 was localized to the vascular endothelium by a 
combination of RT-PCR from murine aorta and immunohistochemistry of 
primary aortic endothelial cells. An antibody against rat Gpr41 was 
characterized and showed to reliably detect murine Gpr41 by 
immunohistochemistry and western blotting. Furthermore, attempts are 
made to localize Gpr41 in the kidney by immunohistochemistry of Gpr41 
WT tissue sections; Gpr41 KO serves as control to validate antibody-
based detection.  
 
Although Gpr41 and Olfr78 have been deorphanized and shown to be 
SCFA receptors, there are other small molecule agonists and partial 
agonists for these receptors that have been identified. For instance, 2-
hydroxybutyrate, a ketone body has been shown to be a Gpr41 agonist 
by several groups, while other groups argue that it’s an antagonist of 
Gpr41. On a different note, lactate was shown to be a ligand for Olfr78 
and it plays a role in Olfr78 our work is to understand the role of these 
receptors in blood pressure regulation, it is crucial to assess receptor 
activation by novel ligands in-house, to identify target molecules that 
could affect blood pressure via these receptors. Activation of Gpr41 by 2- 
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hyrdoxybutyrate and activation of Olfr78 by sodium lactate was assayed. 
Since these receptors respond to SCFAs in circulation and SCFAs are 
mainly a by-product of microbial metabolism, it is important to assess 
receptor activation by “microbial” SCFAs that are a complex mixture of 
individual SCFA species, in contrast to purified SCFA salts used in most 
laboratory assays. Activation of Olfr78 and OR51E2 by “microbial” 






In this section, we will investigate and establish the localization and the 
ligands for Gpr41, and will additional investigate the ligand profile for 
Olfr78. With regards to the tissue localization of Gpr41, there is a minor 
conflict in the literature. According to different reports, Gpr41 is 
expressed in adipose tissue, lungs, heart, kidneys, enteroendocrine cells 
in the colon, sympathetic nervous system and blood vessels[26, 37, 38, 
93-95]. Expression of Gpr41 in blood vessels is of most importance in 
order to attempt to understand its role in BP regulation. All three SCFAs 
receptors, Gpr41, Gpr43 and Olfr78 are expressed in major blood vessels 
– the aorta, renal artery and the iliac artery[5, 26]. X-gal staining in the 
Olfr78 KO tissues (LacZ inserted into Olfr78 coding region, driven by the 
native Olfr78 promoter) co-localizes with smooth muscle actin, indicating 
the expression of Olfr78 in vascular smooth muscle cells[26]. Since 
Olfr78 and Gpr41 act to oppose each other and Gpr41 is likely involved 
in mediating a hypotensive response to SCFAs, the cell type in which 
Gpr41 is expressed in a blood vessel is key to understand it’s 
physiological role and downstream signaling components.  
 
Blood vessels are comprised of outer vascular smooth muscle cell layers 
and an inner single cell layer of endothelial cells. Cellular pathways that 
mediate vasodilation and vasoconstriction are different in these two cell 
types. The endothelial cell layer initiates signaling in response to shear 
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stress or stimuli in the blood to elicit a change in the compliance of 
vascular smooth muscle cells via the secretion of vasoactive substances. 
In addition, the endogenous G – proteins available for signaling may be 
different in the vascular smooth muscle cells and endothelial cells. 
Identifying cell type of Gpr41 expression is key to understanding its 
signaling machinery and pathway.  
 
Metabolites produced by commensal microbiota modulate host pathways 
by acting as ligands for host receptors and GPCRs, allowing for an 
entirely novel paradigm of microbe-to-host GPCR signaling pathways[10-
15]. One well – studied class of microbial metabolites is SCFAs, produced 
by breakdown of complex dietary polysaccharides by Bacterioides, 
Clostridiales and Bifidobacteria[22, 39, 96]. SCFA concentrations peak in 
the colon after a meal, following which they are transported into the 
bloodstream by SCFA transporters or free diffusion[13, 26, 97]. SCFAs 
have been shown to act as ligands for several GPCRs, referred to as free 
fatty acid receptors, Gpr41, Gpr43, Gpr109a and Olfr78. In addition to 
GPCR – mediated effects in the host, SCFAs can mediate receptor – 
independent effects by modulating histone acetylation and cell 
proliferation. SCFAs have been shown to affect host adiposity and 
metabolism, immune system and blood pressure[26, 96-104]. Being a 
class of major microbial metabolites, it is important to understand the 
cellular effects mediated by SCFAs and their signaling pathways. In the 
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future, it is especially exciting to consider that modulating metabolite 
production by the gut microbiota may be a useful tool to obtain beneficial 
effects on host physiology. 
 
Although broadly known as SCFA receptors, Gpr41 is activated by 
acetate, propionate and butyrate while Olfr78 is activated by acetate and 
propionate[26, 37, 38, 94, 105]. In addition to these ligands, there have 
been reports in the literature about a few small molecule ligands for 
these receptors[25, 43, 93, 106]. Olfr78, like all other olfactory receptors, 
couples to Golf in the nasal epithelium and in heterologous systems, can 
couple and signal via native Gs (stimulatory G – protein) in the cell[107]. 
This fact is utilized to assess the ability of small molecules to act as an 
agonist for Olfr78. A dual luciferase system with a constitutive luciferase 
renilla, that acts as control and a CRE – driven luciferase firefly which is 
expressed upon an increase of cellular cAMP elicited by GPCR activation 
is used to test potential ligands for Olfr78 (Figure 4.1). Since activation is 
read out as an increase in firefly expression driven by increased amounts 
of cytosolic cAMP generated by Gs activation, this assay cannot be 
directly used to assay Gi coupled receptor activation, which decreases 
cytosolic cAMP. Therefore, an additional step is used to adapt this Gs 
based GPCR assay to extend it for screening ligands for Gi coupled 
GPCRs like Gpr41. Forskolin is added to the cells to increase cytosolic 
cAMP and ligand addition, which activates Gi would decrease cAMP 
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levels leading to an observable decrease of firefly from forskolin treated 
cells, compared to ligand and forskolin treated condition.  
 
3.3 Materials and methods 
 
RT-PCR from murine aorta 
Reverse transcript – PCR (RT-PCR) was used to localize Gpr41. Thoracic 
aortas were dissected from 3 month old C57BL/6 male mice and total 
RNA was extracted using Qiagen RNeasy Mini kit with DNAse digest 
performed before elution. To remove the endothelium, thoracic aortas 
were sliced open longitudinally and the endothelium was mechanically 
denuded before RNA extraction was performed. RNA was reverse 
transcribed using Biorad iScript reverse transcriptase kit (random 
primers), according to the protocol provided in the kit. Primer sequences 
for Gpr41, eNOS and β-actin are given in Table 2.1. In a subset of 
samples, reverse transcriptase was omitted from the RT reaction (mock 
RT) as a negative control. PCR was carried out using Invitrogen Platinum 







Table 3.1: Primer sequences for RT-PCR 
Gpr41 (685 bp) Fwd: ACGGCGGTGAGCATCGAACG 
Rev: TTCCACCCCCTCCTGCGGTC 
β-actin (353 bp) Fwd: GCTCGTCGTCGACAACGGCTC 
Rev: CAAACATGATCTGGGTCATCTTCTC 





Human embryonic kidney cells stably expressing the SV40 large T-
antigen (HEK293T) were grown in Dulbecco’s modified Eagle’s medium 
supplemented with 10% fetal bovine serum and 2mM L-glutamine 
(described below). Cells were grown in a humidified incubator of 95% 
air/5% CO2 at 37C. Cells were frozen in culture medium with 10% 
DMSO added.  
 
HEK 293T cell medium (500ml) 
DMEM, 4.5 g/L glucose 450 ml 
Fetal bovine serum (FBS) 50ml 
Penicillin / Streptomycin 5ml 




Human umbilical vein endothelial cells (pooled) were grown in MCDB – 
131 basal medium with 20% FBS, 2mM L – Glutamine, Heparin and 
endothelial cell growth substrate (composition below). Cells were grown 
in a humidified incubator of 95% air/5% CO2 at 37C. Cultures were 
propogated by trypsinzing and passing cells. A freezing medium of 
culture medium with 10% DMSO was used. 
 
HUVEC cell medium (500 ml) 
MCDB-131 basal medium 400ml 
Fetal bovine serum (FBS) 100ml 
Penicillin / Streptomycin 5ml 
L – Glutamine 5ml 
Endothelial cell growth substrate 50 μg / ml 
Heparin sodium 50 μg/ml 
 
Medium for primary aortic endothelial cells 
Primary aortic endothelial cells were isolated as follows 
Ø Aortas were harvested from Gpr41 WT and KO mice and cut into 2-
3 mm rings 
Ø Aortic rings were cut open to expose intima, suspended in DMEM 
with 2mg/ml collagenase A, pennicillin, streptomycin and 
amphotericin and gently agitated for 30 minutes at 37C. 
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Ø The medium with aortic rings was centrifuged at 1000xg for 3 
minutes and the pellet was resuspended in DMEM with 20% FBS, 
penicillin, streptomycin and amphotericin and placed in a 
collagen-coated tissue culture dish. 
Ø Aortic rings were removed in 2 hours and the medium was 
replaced with primary endothelial cell growth medium described 
below.  
Ø Endothelial cells grew to confluency in 2 weeks after isolation 
 
Primary aortic endothelial cell medium 
DMEM / F12 400ml 
Fetal bovine serum (FBS) 100ml 
Penicillin / Streptomycin 5ml 
Amphotericin 50 μg/ml 
L – Glutamine 5ml 
100X Non-essential amino acid mix 5ml 
Endothelial cell growth substrate 50 μg/ml 
Heparin sodium 50 μg/ml 
 
HEK293T cell transfection with lipofectamine 2000 
Lipofectamine 2000 (Invitrogen) was used to transiently transfect Gpr41 
and Olfr78 into HEK293T cells according to manufacturer instructions. 
Reverse transfections were performed, HEK293T cells were passed onto 
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12 – well dishes (on coverslips for immunofluorescence, in dishes for 
western blotting) and transfected simultaneously. 
 
Cell immunofluorescence staining protocol 
HEK293T cells transfected with Gpr41 or any other olfactory receptor 
and non-transfected cells (control) were grown on coverslips for 24 hours 
post-transfection. Immunostaining was performed 24 hours after 
transfection. The protocol followed comprised of the following steps 
1. Coverslips were washed in cold PBS++ 
2. Cells were fixed with 4% formaldehyde in PBS++ for 30 minutes at 
room temperature 
3. Coverslips were washed in PBS++ and cells were permeabilized for 15 
minutes. (Permeabilization buffer: 0.1% BSA, 0.3% Triton – X 100 in 
PBS++) 
4. Blocking was carried out with 1% BSA in PBS++ for 30 minutes 
5. Cells were incubated overnight with primary antibody (anti – Gpr41 
polyclonal, raised in rabbit, monoclonal flag antibody, raised in mice) 
at 1:100 dilution in blocking buffer. 
6. After three washes with permeabilization buffer, coverslips were 
incubated with fluorescent tagged secondary antibody (1:1000 in 
blocking buffer) and Hoescht (nuclear stain, 1:2500) for 45 minutes at 
room temperature 
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7. Coverslips were washed and mounted with vectashield and viewed 
under a fluorescence microscope. 
 
Tissue immunostaining protocol 
This protocol was used to stain tissue sections from Gpr41 KO and 
Gpr41 WT mice. Mice were euthanized by CO2 asphyxiation and tissues 
were harvested. The harvested tissues were post fixed in 10% neutral 
buffered formalin for 2 days and sucrose treated for 3 days following 
which they were set in blocks with OCT for sectioning. The blocks were 
sectioned to get 10 – 12 μM tissue cryosections for immunostaining. The 
following steps were performed: 
1. Slides were washed in 1X TBS 
2. Antigen retrieval in citrate buffer was performed with 10mM citrate 
buffer, pH 6.0. Citrate buffer was preheated and slides were placed 
in hot citrate buffer for 20 minutes and then allowed to cool down 
to room temperature.  
3. Slides were washed in TBS and placed in s 1% SDS solution in 
TBS for 5 minutes, then washed again in TBS.  
4. Blocking was carried out with 1% BSA and 0.2% milk in TBS, for 
30 minutes at room temperature. 
5. Sections were incubated overnight in a humidified chamber with 
primary antibody, diluted appropriately in blocking buffer. 
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6. Slides were washed first in TBS with 0.1% BSA, then in TBS with 
0.1% BSA and 0.8% NaCl and then in TBS – 0.1% BSA. 
7. Sections were then incubated with secondary antibody (fluorescent 
labeled) at 1:1000 dilution with Hoescht stain at 1:2500 dilution 
for 45 minutes at room temperature. 
8. After secondary labeling, slides were washed similarly (step 6), with 
an additional wash in TBS in the end. 
9. Slides were dried and mounted in vectashield and observed 
through a fluorescence microscope. 
 
Buffers for tissue immunohistochemistry 
Citrate buffer for antigen retrieval 
5ml of 0.1 M Citric Acid) and 45 ml 0.1 M Na citrate in 500 ml total.  
 
1% SDS in TBS  
12.5 ml 20% SDS in 250ml total TBS 
 
Blocking buffer 
TBS with 1% BSA and 0.2% blocking milk 
 
TBS/HS/BSA 




500ml TBS, 0.5g BSA 
 
SDS-PAGE 
Protein samples were resolved using sodium dodecyl sulfate 
polyacrylamide gel electrophoresis (SDS-PAGE). Cell lysates were mixed 
with 5X Laemmli buffer and heated at 95C for 5 minutes and cooled 
before loading. SDS-PAGE gels with a 3% stacking gel and 12% resolving 
gel were cast and loaded with samples and molecular weight markers. 1X 
western running buffer was used to resolve the lysates on the gel. 
 
Western blotting 
Following resolution of cell lysates by SDS-PAGE, the samples are 
electrophoretically transferred onto nitrocellulose membrane. Proteins 
were transferred at 100V for 90 minutes in 1X transfer buffer. Upon 
completion of transfer, the membranes were stained with Ponceau S to 
visualize transferred protein bands. The membrane was then blocked 
with 5% non-fat milk in PBS with 0.1% Tween 20 for 30 minutes and 
then incubated with primary antibody overnight in blocking milk. After 
incubation with primary antibody, the membrane was washed in PBS-T 
(1X PBS with 0.1% Tween 20) and incubated with secondary antibody 
(HRP linked) in milk for 1 hour at room temperature. The blot was 
developed with chemiluminescent ECL substrate after washing the 
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membrane thoroughly, following incubation with secondary antibody. 
Dilutions of primary and secondary antibody are listed below 
Primary antibodies 
Gpr41: 1:1000 in milk, overnight 
Mflag: 1:1000 in milk, overnight 
Secondary antibodies 
Goat anti mouse, HRP tagged: 1:10,000 in milk, 1-hour incubation 
Goat anti rat, HRP tagged: 1:10,000 in milk, 1-hour incubation 
 
Dual luciferase assay to monitor Gs coupled GPCR activation 
Ø HEK293T cells are plated in 96 – well black plates. 
Ø The cells were transfected with olfactory receptor / GPCR 
construct (71%), luciferases firefly and renilla (14% each) using 
lipofectamine, according to manufacturer instructions. 
Ø 20 hours post transfection, media is removed, cells are washed 
with PBS and incubated with STIM (CD293) medium for 30 
minutes to decrease background cellular signaling. 
Ø Ligands to be tested are prepared in various concentrations and 
75μl ligand is added to each test wells. Non-treated wells are used 
as control. Cells are incubated with ligands for 4 hours.  
Ø After ligand incubation, cells are washed and lysed in passive lysis 






B. vulgatus culture 
Bacillus vulgatus, an isolated human colonic bacterial species, known to 
produce SCFAs was grown in brain heart infusion medium under 95% 
CO2 for 48 hours.  
 
Buffers 
Ø 50X TAE (1 liter) 
242g Tris base (MW=121.14) 
57.1ml Glacial Acetic Acid 
100 mL of 0.5 M EDTA (pH 8.0) 
pH 8.5 
 
Ø 10X Tris buffered saline (TBS, 1 liter) 
24.08g Tris base 
80g NaCL 
13ml 6M HCl 
pH to 7.6 with HCl 
 
Ø 10X Phosphate buffered saline (PBS, 1 liter) 
25.6 g Na2HPO4·7H2O 
80 g NaCl 
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2 g KCl 
2 g KH2PO4 
 
Ø 10X SDS – PAGE running buffer 
35mM SDS 
250mM Tris base 
1.92M Glycine 
 
Ø 10X transfer buffer 
250mM Tris base 
1.92M Glycine 
1X buffer made up with 20% Methanol. 
 





0.1% Triton X-100 
Protease inhibitor cocktail 
 
Ø Laemmli buffer 
0.1% 2-Mercaptoethanol 
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Gpr41 KO does not have detectable expression of β – galactosidase 
Initial attempts to localize Gpr41 in tissue were made using commercially 
available antibodies, X-gal staining and β – galactosidase antibody 
staining in Gpr41 KO mice. Commercially available antibodies for Gpr41, 
shown to detect Gpr41, were found to be unreliable in our hands[108, 
109]. Although sc-131166, raised against the amino acid 106 – 180 of 
human Gpr41 was reported to recognize Gpr41 in tissues[108], in our 
hands it gave similar staining in Gpr41-/- and Gpr41+/+ mice. On the 
other hand, sc-98332[109], raised against a cytoplasmic epitope of 
human Gpr41, failed to recognize overexpressed Gpr41 in HEK293T 
cells. Gpr41 KO mice have LacZ inserted into the coding region of 
Gpr41[10]. X-gal staining was not detected in tissues from Gpr41 KO. 
Staining with β – galactosidase antibody also did not detect expression of 
lacZ specific to Gpr41 KO tissues (Figure 3.2). Interestingly, Gpr41 
doesn’t have a defined promoter, the expression of Gpr41 is driven by the 
promoter of Gpr40, which is the adjacent gene in the chromosome, via an 











Olfr78 and OR51E2 – lactate 
A recent study reported that lactate was an agonist of Olfr78 and Olfr78 
is expressed in the oxygen – sensitive glomus cells in the carotid 
body[106, 112]. The carotid body controls respiration rate and monitors 
blood oxygen levels[112]. In Olfr78 KO mice, lactate – induced 
hyperventilation is not observed, raising the possibility that Olfr78 KO 
could be activated by lactate[106]. Unlike the SCFAs, which are produced 
primarily as byproducts of microbial metabolism, lactate is generated in 
muscle under hypoxia and stress[23, 113]. If lactate were a strong 
agonist of Olfr78, that would add another layer of complexity to the blood 
pressure regulation pathway involving Olfr78 and Gpr41. D – Lactate 
and L – Lactate were tested in various concentrations with Olfr78 and 
OR51E2 to see if the receptors were activated by either enantiomer of 
lactic acid. L – Lactate appeared to activate Olfr78 at relatively higher 
doses compared to acetate and propionate and appeared to be, at best, a 
partial agonist (Figure 3.11).  
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Table 3.2 EC50s of Olfr78 for SCFAs and lactate 
Ligands EC50 (mM) 
Sodium acetate 4.269 
Sodium propionate 4.941 
Sodium L - lactate 21.3949 
 
OR51E2 was screened with similar doses of lactate to test the responses 
of the human ortholog. While Olfr78 had a weak response at high 
concentrations of lactate, OR51E2 did not exhibit any activation upon 










































Figure 3.12 OR51E2 is not activated by lactate. Activation of OR51E2 is 
observed in a dose – dependent manner with acetate and propionate, 
while lactate doesn’t show activation at any of the doses tested. * p<0.05, 
in comparison to non-treated (0mM) values.  
 
Activation of Olfr78 and OR51E2 by “microbial” SCFAs 
Although Olfr78 and OR51E2 have been de-orphanized and shown to be 
SCFAs receptors, the SCFAs used for the de-orphanization assays were 
mostly purified sodium salts. SCFAs as made by the commensal 
microbiota is a complex mixture of different moieties mainly in the 
carboxylic acid form in contrast to the purified SCFAs which are in the 
ionized salt form. In order to derive SCFAs produced as a byproduct of 
microbial metabolism, filtered culture supernatant from an isolated 
species of human colonic bacteria, Bacillus vulgatus was obtained. The 
culture supernatant was used to screen Olfr78 and OR51E2 in a 
luciferase assay to monitor activation of the receptors by “microbial” 
SCFAs. Bacillus vulgatus is known to produce large quantities of SCFAs 
by breaking down dietary polysaccharides. Isolated Bacillus vulgatus is 
grown in brain heart infusion medium, background activation by the 
medium and by the culture supernatant were compared to assess 
activation of the receptors by microbial SCFAs. Both Olfr78 and OR51E2 
(Figure 3.13) are activated by culture supernatant from Bacillus vulgatus, 





SCFA metabolites act via GPCRs – Gpr41 and Olfr78 to modulate blood 
pressure. Gpr41 and Olfr78 are both expressed in major blood vessels 
and Olfr78 is expressed in the vascular smooth muscle cells and renal 
afferent artery. Based on acute dose responses, it was inferred that 
Olfr78 mediates a hypertensive response upon activation, while Gpr41 
mediates a hypotensive response. The aim of the experiments presented 
in this section was to understand the cellular localization of Gpr41 in 
blood vessels, kidney and other tissues and to characterize ligands for 
Gpr41 and Olfr78. The major findings reported in this section are that 
Gpr41 is expressed in the vascular endothelium (by RT-PCR and 
antibody staining of primary mouse aortic endothelial cells) and renal 
glomeruli (tissue immunohistochemistry).  
 
Gpr41 and Olfr78 are SCFA receptors that get activated by a variety of 
SCFA moieties. In addition to SCFAs, there are several reports of small 
molecules that act as agonists for Olfr78 (lactate, for instance) and 
Gpr41 (β – hydroxybutyrate). Since the role of these receptors in blood 
pressure regulation is our primary interest, it is crucial to identify the 
ligand range of these receptors and the sources of these ligands in order 




Gpr41 in the endothelium 
Localization of murine Gpr41 to the vascular endothelium is consistent 
with previous reports of human Gpr41 and Gpr42 expression in the 
endothelium of adipose tissue vasculature. Initially, it was thought that 
Gpr41 was expressed in adipose tissue since it was detected by RT-PCR 
in adipose tissue and played a role in regulating adiposity. Subsequently, 
Brown et.al. showed that hGpr41 and Gpr42 localized to the vasculature 
in adipose tissue, the vascular endothelium in particular.  
 
The endothelial cell layer of blood vessels senses blood pressure and rate 
of flow by monitoring shear stress through their cilia. Being the inner 
layer of cells in a blood vessel, substances in circulation can affect 
endothelial cell function either directly by diffusing into the cell or by 
activating cell surface receptors in the cell. GPCRs in endothelial cells 
have been shown to detect shear stress and respond to reactive oxygen 
species in the cell. Expression of a SCFA receptor in endothelial cells is 
very interesting and is a novel finding regarding GPCR expression in the 
endothelium and their physiological role.  
 
Endothelial cells secrete signaling molecules that act on the vascular 
smooth muscle cell layer to modulate their stiffness, thereby modulating 
vascular resistance and blood pressure. There are several well-studied 
mechanisms by which endothelial cells mediate vasodilation and 
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vasoconstriction. eNOS based nitric oxide signaling, prostacyclins and 
endothelial-derived hyperpolarizing factor mediate vasodilation, while 
endothelin and mediate vasoconstriction. Since Gpr41 mediates a 
hypotensive response upon activation, the localization of Gpr41 in the 
endothelium narrows down the potential signaling mechanisms to a 
handful of pathways by which the endothelium mediates vasodilation 
and subsequent decrease in BP. Furthermore, if the pathway of Gpr41 
signaling is identified and validated, Gpr41 agonists can be used to 
target key downstream components to decrease BP in hypertension.  
 
Localization of Gpr41 in renal glomeruli 
It was previously shown that Gpr41 is expressed in the vasculature and 
kidney, but localization to a precise cell type / structure in the kidney 
has not been established until now. Glomeruli are complex structures 
comprised of podocytes, epithelial cells and blood vessels. Localization of 
Gpr41 in the glomeruli could mean that Gpr41 potentially plays a role in 
renal function and regulation of glomerular filtration rate. It is important 
to identify the cell type of Gpr41 expression in the glomerulus to infer 
more about its function in the kidney. Analysis of gene expression in 
human studies have showed Gpr41 to be in top 10% under expressed in 
glomerulosclerosis[114], indicating that Gpr41 could play a very 
important role in regulating renal function. 
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Olfr78, also a SCFA receptor that mediates a hypertensive response to 
SCFAs is expressed in the renal afferent artery. Expression of Gpr41 in 
the glomerulus puts Olfr78 and Gpr41 in adjacent cell types in the 
kidney. Given that they have opposing effects on blood pressure, it is 
crucial to understand their function in the kidney and determine if their 
renal effects oppose or augment each other. Olfr78 stimulates renin 
secretion from the renal afferent artery upon activation; it would be 
interesting to compare the renal effect of Gpr41 to plasma renin 
concentration to determine if Olfr78 and Gpr41 exhibit crosstalk in the 
kidney. 
 
β – hydroxybutyrate and Gpr41 
β – hydroxybutyrate is a ketone body produced under starvation 
conditions. In contrast to SCFAs, that are primarily produced by 
commensal microbiota, β – hydroxybutyrate is endogenously produced. 
Activation of Gpr41 by β – hydroxybutyrate is of great interest because 
that would identify an innate mechanism by which hypotension is 
induced in periods of prolonged physical activity or during starvation, to 
conserve energy. Given that there were conflicting reports in literature as 
to the nature of β – hydroxybutyrate’s effect on Gpr41, it was important 
to assess its effect in the assay setup in house. In our hands, β – 
hydroxybutyrate works as a Gpr41 agonist. This indicates that Gpr41 
may be activated by pathways other than microbe mediated to decrease 
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blood pressure. Furthermore, Gpr41 is also expressed in the sympathetic 
nervous system. Ketone bodies provide energy source for the brain 
during prolonged starvation. There could be novel mechanisms by which 
Gpr41 plays a role in energy metabolism via β – hydroxybutyrate. 
 
Lactate and Olfr78 
It was recently shown that lactate activated Olfr78 expressed in the 
carotid body[106, 112]. Like β – hydroxybutyrate, lactate is also 
produced during starvation, mostly in muscle during exercise. According 
to the study, Olfr78 had an EC50 of 4mM for lactate. Since Olfr78 elicits 
a hypertensive response upon activation, it was important to test the 
activation of Olfr78 by lactate in our luciferase assay setup to verify its 
ability to activate the receptor. Upon extensive testing of lactate – 
mediated activation of Olfr78, it appeared that lactate is a weak, partial 
agonist of Olfr78 with ~ 20mM EC50 and the human ortholog of Olfr78, 
OR51E2 is not activated by lactate. This means that detection of lactate 
could be an allosteric effect that the murine ortholog exhibits, whereas 
that ability is not seen in the human ortholog. In contrast, SCFAs elicit a 
response from both Olfr78 and OR51E2, indicating that the ability to 
detect SCFAs has been conserved through evolution, reinforcing the role 




“Microbial” SCFAs and Olfr78  
De-orphanization assays to identify ligands for orphan receptors usually 
utilize purified chemical ligands that are a single isolated species. On the 
other hand, when SCFAs are made by the microbiota, it’s a complex 
mixture of formate, acetate, propionate, butyrate, lactate and a few other 
minor SCFA species in the native state, not ionized in the salt forms. 
Mixtures of ligands and purity of ligands greatly influence the activation 
seen in vitro. Analysis of Olfr78 and OR51E2 activation with culture 
supernatants from isolated colonic bacterial strains known to produce 
SCFAs showed that microbially produced SCFAs could in fact activate 
the receptors. This can be very useful in further experiments looking at 
the effect of diet on increasing plasma SCFAs in order to activate Gpr41 




4 Role of Gpr41 in blood pressure regulation 
 
4.1 Abstract 
Plasma electrolytes play a very important role in blood pressure 
regulation and renal function. Here, ten major plasma electrolytes and 
parameters were assessed in male and female Gpr41 KO and WT mice. 
There were no significant differences in plasma electrolytes between the 
genotypes / sexes. Plasma renin concentration (PRC) was assessed in 
Gpr41 KO and WT mice of 3 months and 6 months of age. There were no 
differences in the PRC of 3-month-old mice, while older 6-month-old KO 
mice tended toward a slight increase in PRC. Furthermore, renal 
morphology of Gpr41 KO and WT was studied and it appears that Gpr41 
KO mice trend towards having smaller glomeruli.  
 
Previously, acute bolus of SCFA (sodium propionate) was shown to 
mediate a quick and sharp decrease in BP with an equally quick 
recovery. Based on acute dose responses, it was hypothesized that Olfr78 
mediates a hypertensive response to SCFAs and Gpr41 mediates a 
hypotensive response. Since Gpr41 mediates a decrease in BP, we 
hypothesized that Gpr41 knockout (KO) mice would be hypertensive at 
baseline. Concordant with our hypothesis, we found that Gpr41 KO (n=8) 
exhibit isolated systolic hypertension and elevated pulse pressures 
compared to wild-type (WT, n=6) mice; diastolic BP and heart rate was 
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not different between genotypes. In agreement with a phenotype of 
systolic hypertension, KO mice also exhibited elevated pulse wave 
velocity in vivo, but surprisingly, no increase in ex-vivo aorta stiffness 
(measured by tensile testing experiments). 
 
Hypothesis: (i) Gpr41 KO mice would exhibit hypertension. 
(ii) Chronic SCFA administration would elevate systolic BP in Gpr41 KO 
(iii) Gpr41 KO may not exhibit salt sensitive hypertension 
 
Acute sodium propionate doses decrease BP via Gpr41, while Olfr78 
increases BP via a renin-dependent pathway. Sodium propionate was 
chronically administered to Gpr41 KO and WT mice to monitor its effect 
on BP and to explore the potential of elevation of plasma SCFAs by 
dietary intervention and its effect on BP. Chronic administration of 
200mM sodium propionate (a Gpr41 ligand) and 200mM NaCl (control) 
did not significantly affect BP in Gpr41 WT or KO, although systolic 
pressure trended toward an increase for both treatments and genotypes. 
We hypothesize that the hypertensive effect of propionate in the KO is 
mediated by another SCFA receptor, Olfactory receptor 78, which 
increases in BP upon activation.   
 
To determine the salt-sensitivity of hypertension observed, 3-month-old 
Gpr41 KO and WT mice were switched to a control diet with 0.49% NaCl 
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and implanted with telemetry devices. Following a baseline BP 
measurement, the mice were switched to a high salt diet (4% NaCl) for a 
week and then switched to a low salt diet (0.04% NaCl) for 5 days. 
Analysis of data obtained from this experiment shows that hypertension 
in Gpr41 KO mice is not salt sensitive, there is no increase of BP 
observed on the high salt diet. However a decrease in BP when moved 





Hypertension is widely prevalent in today’s adult population with ~30% 
adults having higher than normal BP values. Cardiac output and 
systemic vascular resistance regulate mean arterial pressure. The control 
of BP is complex and involves an intricate balance between the 
neurohormonal components that regulate vascular resistance, inotropy 
and salt balance. In addition to physiological factors, diet and lifestyle 
play major roles in the development of hypertension in individuals. 
Chronic hypertension, if untreated, leads to the development and 
progression of cardiovascular disease and associated complications. 
Despite the current pharmacological intervention methods for 
hypertension, some individuals develop resistant hypertension that 
mounts a greater challenge. BP regulation mediated by microbial SCFA 
metabolites offers an exciting novel pathway that could potentially be 
targeted by therapeutics.  
 
Previous work in the Pluznick lab showed that Gpr41 is involved in blood 
pressure regulation by microbial SCFAs, and that acute activation of 
Gpr41 lowers blood pressure[5, 26]. Therefore, it was hypothesized that 
Gpr41 KO mice would be hypertensive in comparison to Gpr41 WT mice. 
To test this hypothesis, baseline blood pressure was measured in 3-
month-old male Gpr41 WT and KO littermates using a telemetry – based 
continuous blood pressure monitoring system from DSI.  
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Since Gpr41 is expressed in the kidney and vasculature and Gpr41 KO 
mice exhibit a BP phenotype, it is important to analyze plasma 
electrolytes to assess renal function. The iSTAT method offers an easy 
way of estimating various plasma solutes and ions. Any obvious 
differences in plasma electrolytes between genotypes could indicate 
toward a defect in ion handling by the kidney or electrolyte homeostasis.  
 
Olfr78 works via an increase in plasma renin concentration (PRC) to 
increase blood pressure. Since chronic propionate administration did not 
produce a stable increase in BP in Gpr41 KO mice, PRC was measured in 
Gpr41 KO and WT mice to assess if there were any differences due to 
systolic hypertension. Finally, morphology of kidney sections from Gpr41 
KO and WT mice were observed to identify any gross changes in histology 
in the KO mice, since Gpr41 was identified in the glomerulus.  
 
Blood pressure can measured by a couple of methods in animals, a tail 
cuff measurement for mice that is easier, but relatively inaccurate and 
continuous telemetry that involves implantation of pressure transmitters 
in the mice. Telemetry for blood pressure measurement is carried out 
with a pressure sensor and transmitter with a 5.0 cm catheter that is 
threaded in through the carotid artery to have the tip of the device 
situated in the free – flowing blood in the aortic arch (Figure 5.1). PA-C10 




This increase in PWV causes the reflected pressure wave to return earlier 
to the heart and increase pressure in late systole. 
 
It was previously demonstrated that acute intravenous delivery of SCFAs 
caused a rapid hypotensive response in wild-type mice, but a 
hypertensive response in Gpr41 KO mice[5, 26]. The nature of this blood 
pressure response observed to acute SCFA infusion was rapid and short 
– lived. SCFAs also trigger renin secretion from the juxtaglomerular 
apparatus, via Olfr78, which in-turn increases blood pressure[26]. The 
time course of this renin response is much slower and gradual compared 
to the blood pressure response. Olfr78 KO mice have lower renin 
secretion from the juxtaglomerular apparatus and exhibit a decrease of 
blood pressure in response to acute SCFA administration[26]. Gpr41, on 
the other hand decreases blood pressure and it was established that 
Gpr41 KO mice have higher systolic pressure. Gpr41 KO and WT mice 
were subjected to chronic SCFA delivery via drinking water to 
understand the mechanism of chronic SCFA signaling and to see if the 
acute effects observed would replicate in the chronic treatment scenario. 
The objective of the experiments presented in this section is to test the 
hypothesis that chronic SCFA treatment will similarly alter BP in wild 
type mice and Gpr41 KO mice.  
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A combination of dietary and genetic factors contribute to the 
development and manifestation of hypertension in an individual. In 
humans, dietary salt intake is an important causative factor that leads to 
hypertension, although the salt susceptibility of blood pressure varies in 
different individuals. Salt–sensitive hypertension develops in individuals, 
whose kidneys have an impaired ability to handle excess salt, leading to 
sodium retention, which increases BP by increasing cardiac output. Salt 
sensitivity of an individual can lead to the development of primary 
essential hypertension or can exacerbate an existing hypertensive 
condition, resulting in a three-fold increase of the occurrence of 
cardiovascular complications[117-119].  
 
Since Gpr41 KO mice present with isolated systolic hypertension at 
baseline and Gpr41 localized to the glomeruli in kidney sections, it was 
important to assess the salt – sensitivity of the blood pressure 
phenotype. Exacerbation of the hypertension phenotype observed would 
indicate that sodium loading results in sodium retention and impairs the 
ability of kidneys to handle salt. Furthermore, if Gpr41 KO mice 
exhibited salt-sensitive hypertension, it forms a further link between 





5.3 Materials and methods 
 
Animal handling 
Mice were housed in accordance with institutional, state and national 
guidelines. All experimental protocols were approved by the Johns 
Hopkins University Institutional Animal Care and Use Committee 
(accredited by the AALAC). Gpr41 KO (a kind gift from Drs. Yanagisawa 
(UT Southwestern) and Gordon (Washington University)[10] were 
backcrossed onto C57BL/6 mice, and Gpr41 heterozygotes were then 
bred in-house to obtain Gpr41 KO and Gpr41 WT littermates. All animals 
were fed and watered ad-libitum.  
 
Blood chemistry and plasma electrolytes 
Blood chemistry of Gpr41 mice was analyzed using iSTAT Chem8+ 
cartridge with handheld iSTAT system 1 using samples taken from the 
superficial temporal vein.  
 
Plasma renin concentration 
Plasma renin concentration was measured using a modified angiotensin–
I measurement kit (Peninsula labs S-1180). Prior to starting the assay, 
plasma was diluted 15 fold and incubated with excess porcine 
angiotensinogen (Sigma SCP0021) for 20 minutes at 37°C in a buffer 
containing 50mM sodium acetate (pH 6.5), 10mM AEBSF, 10mM EDTA 
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(pH 8.0), 1uM porcine angiotensinogen and 10mM 8-hydroxyquinoline. 
After incubation with angiotensinogen, the samples were analyzed 
according to the protocol provided with the kit. Plasma renin activity was 




Kidneys were harvested from 3-month-old Gpr41 KO and WT mice and 
post-fixed in 10% buffered formalin. After fixation, the kidneys were set 
in paraffin blocks, section and stained with H&E to visualize histology. 
 
Blood pressure measurement 
 DSI TA11 PA-C10 devices were used to measure BP by radiotelemetry in 
Gpr41 KO and WT mice. 3-month-old male Gpr41 KO and WT mice were 
implanted with PA-C10 devices under 2% isoflurane anesthesia and 
allowed 7 days for recovery. BP was recorded continuously in the 
implanted mice after recovery. A 5-day recording period was used to 
assess baseline BP. Subsequently, mice were chronically treated with 
200mM sodium propionate (Sigma P1880) in the drinking water for 7 
days, followed by a return to regular water for 5 days, and then an 
additional 5 days with 200mM sodium chloride (equimolar sodium 
control, Fisher S641-212) in the drinking water. A separate cohort of age-
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matched mice (no telemetry) on the same sequence of treatments was 
used to monitor body weights.  
 
In order to assess the salt – sensitivity of blood pressure in Gpr41 KO 
and WT mice, they were subjected to 7 days of high salt diet (4% NaCl) 
followed by 5 days of low salt diet (0.04% NaCl). Blood pressure was 
continuously recorded during the experimental period. A separate cohort 
of age matched mice was used to monitor body weights and plasma 
electrolytes on the normal, high salt and low salt diets. 
 
Pulse wave velocity 
Pulse wave velocity (PWV) was measured non-invasively in 3 month old 
and 6-month-old male Gpr41 KO and WT mice with a high frequency, 
high-resolution Doppler spectrum analyzer (Indus Instruments, Houston, 
TX). Under anesthesia with 1.5% isoflurane, mice were placed supine on 
a temperature-controlled platform. Core temperature was maintained at 
37°C. Thoracic aortic outflow and abdominal aortic flow profiles were 
captured with two probes. The distance separating the probe locations 
was also measured. PWV was calculated by the thoracic – abdominal 
distance divided by the pulse transit time between flow pulses recorded 
at the thoracic and abdominal aortic sites. DSPW software (Indus 
Instruments) was used for data analysis[120]. 
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Tensile testing of Gpr41 aorta 
Aortas from 6-month-old Gpr41 male mice were harvested and cut into 
2-mm rings and mounted on the pins of an electromechanical puller 
(DMT560; Danish Myo Technology A/S, Aarhus, Denmark). After 
calibration and alignment, the pins were slowly moved apart using an 
electromotor at a rate of 50 lm/sec to apply radial stress on the specimen 
until breakage. Force and displacement were continuously recorded. A 1-
mm segment proximal to the ring was imaged at a 10x magnification. 
The inner and outer diameters of the vessel were measured at 4 locations 
using Image J software (National Institutes of Health [NIH], Bethesda, 
MD). Average inner and outer diameters were used to calculate sample 
thickness. Engineering stress (S) was calculated by normalizing force (F) 
to the initial area of the specimen; S = F 2tl; where t = thickness and l = 
length of the sample. Engineering strain (λ) was calculated as the ratio of 
displacement to initial diameter. The stress-strain relationship was 
represented by the equation S =  α !!"  where α and β are constants, 
determined by nonlinear regression for each sample[121]. A subset of 
aortas were decellularized for this measurement: for this, aortas from 
Gpr41 KO and WT mice were incubated in de-cellularization solution 1 (8 
mM CHAPS, 1 M NaCl, and 25 mM EDTA in PBS) for 44 hours. Next, 
samples were incubated in de-cellularization solution 2 [1.8 mM sodium 
dodecyl sulfate (SDS), 1 M NaCl, 25 mM EDTA in PBS] for 44 hours. The 
de-cellularization solutions were changed every 22 hours with three 15-
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min PBS washes. After incubation in de-cellularization solutions, aorta 
segments were washed and incubated in PBS for 2 days to remove 
residual detergents. All steps were conducted at room temperature under 
constant shaking. Finally, samples were incubated at 37°C for 1 day in 
endothelial cell media (ScienCell Research Labs) and washed thrice in 
PBS for 15-min each, to obtain decellularized specimen. These aortas 
were then analyzed (tensile testing) as described above. 
 
Ex-vivo vascular relaxation experiments 
3-month-old male mice (Gpr41 WT and KO) were euthanized by CO2 
asphyxiation. Proximal segments of the tail artery were dissected rapidly 
and placed in cold Krebs-Ringer bicarbonate solution containing 
118.3mM NaCl, 4.7mM KCl, 1.2mM MgSO4, 1.2mM KH2PO4, 2.5mM 
CaCl2, 25.0mM NaHCO3, and 11.1mM glucose (control solution). The tail 
arteries (either intact or with endothelium denuded) were cannulated at 
both ends with glass micropipettes, secured using 12-0 nylon 
monofilament suture, and placed in a microvascular chamber (Living 
Systems, Burlington, VT)[122, 123]. The arteries were maintained at a 
constant transmural pressure (PTM) of 60 mmHg in the absence of flow. 
The chamber was superfused with control solution, maintained at 37°C, 
pH 7.4, and gassed with 16% O2-5% CO2-balance N2. The chamber was 
placed on the stage of an inverted microscope (20X; Nikon TMS-F) 
connected to a video camera (CCTV camera; Panasonic). The vessel image 
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was projected on a video monitor, and the internal diameter was 
continuously determined by a video dimension analyzer (Living Systems 
Instrumentation) and was monitored using a BIOPAC (Santa Barbara, 
CA) data acquisition system[122, 123]. The tail vessels were allowed to 
equilibrate at PTM of 60mmHg for 30 minutes. After equilibration, the 
vessels were constricted with phenylephrine (PE) and then treated with 
increasing doses of sodium propionate and sodium acetate in the 
superfusate and the internal diameter of the vessels were recorded over 
time. After propionate treatment, the reactivity of the vessels (and 
presence/absence of endothelium) was confirmed by acetylcholine.  
 
SCFAs were delivered orally and blood pressure was continuously 
recorded over the treatment period. As shown in Figure 4.3, after an 
initial baseline measurement (5 days), mice were treated with 200mM 
sodium propionate in the drinking water for 7 days, followed by 5 days 
recovery, 5 days treatment with 200mM NaCl (control) in the drinking 






Plasma electrolytes in Gpr41 KO and WT mice 
Plasma electrolytes were assayed in 3 month old Gpr41 KO and Gpr41 
WT, male and female mice using iSTAT cartridges that measure plasma 
sodium, potassium, calcium, chloride, glucose, creatinine, BUN, anion 
gap, hematocrit, TCO2 and hemoglobin. Similar values of plasma 
electrolytes were observed in the KO and WT mice, both male and female 
(Table 4.1). The mice were not fasted prior to this experiment; so the 
trends in plasma glucose numbers cannot be used for predicting 
metabolic phenotypes. Plasma samples collected exhibit mild hemolysis; 
hence potassium values are higher than normal values. 
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Table 4.1: Plasma electrolytes in Gpr41 KO and Gpr41 WT mice 
    M, WT M, KO F, WT F, KO 
mmol / L Na 146.71±0.61 148.10±0.53 151.5±1.85 148±0.70 
  K 6.01±0.22 6.22±0.29 6.175±0.09 5.525±0.45 
  Cl 116.86±1.3 118.60±1.09 113.25±0.75 113.75±1.38 
  iCa 1.14±0.02 1.17±0.04 1.2925±0.01 1.2425±0.03 
  TCO2 15.29±1.57 15.00±0.84 18.5±1.19 19.5±0.5 
mg/dL Glucose 205.43±11.36 184.70±11.75 182.75±12.17 179±13 
  BUN 18.57±1.46 20.00±0.94 20±1.58 19±61 
  creatinine <0.2 <0.2 <0.2 <0.2 
% PCV hematocrit 46.00±0.44 41.35±4.59 47±1.47 47.75±0.75 
g/dL hemoglobin 15.63±0.15 15.60±0.23 15.975±0.5 16.25±0.27 
mmol/L AnGap 21.43±0.97 21.70±1.08 24.25±1.8 22±1.78 
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Plasma renin concentration 
SCFAs act via Olfr78 to stimulate renin secretion from the 
juxtaglomerular apparatus. Olfr78 localizes to the renal afferent arteriole, 
which stores and secretes renin and vascular smooth muscle cells. 
SCFAs trigger renin secretion from glomerular preparations via Olfr78 
(Figure 4.5); Olfr78 KO mice have lower plasma renin compared to Olfr78 
WT mice. Since SCFA mediated BP increase is via renin, plasma renin 
concentration in Gpr41 KO and WT mice was measured to determine if 
compensatory changes in plasma renin occur in Gpr41 KO mice, which 
could affect baseline blood pressure observed. PRC was measured using 
a modified Angiotensin–I ELISA kit and was determined in terms of ng 
Angiotensin–I produced per ml of plasma per hour. Concentration of 
Angiotensin–I in the samples is determined using a standard curve 
(Figure 4.6). 
 
Shown in Table 4.2 and Table 4.3 are individual plasma renin 
concentration values from 3 – month – old and 6 – month – old Gpr41 KO 
and Gpr41 WT mice. In 3 – month old mice, the average plasma renin 
concentration values of Gpr41 male, WT mice is 105.94±8.57 and that of 
Gpr41 male, KO mice is 115.3±16.25 ng Angiotensin – I produced / ml / 
hour. Gpr41 WT female mice have a plasma renin concentration of 
129.88±5.92 and that of Gpr41 KO female mice is 139.55±9.87 ng 
Angiotensin – I produced / ml / hour. There are no significant differences 
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in the plasma renin concentration between 3 – month old Gpr41 KO and 
Gpr41 WT mice (both male and female). Interestingly, 6 – month – old 
Gpr41 KO male mice have an average plasma renin concentration of 
149.56±32.57 and that of Gpr41 WT mice is 72.66±13.36 ng Angiotensin 
– I produced / ml / hour. In these older mice, Gpr41 KO mice tend 
towards having lower plasma renin activity, though not significant. This 
indicates that the isolated systolic hypertension phenotype observed is a 
vascular phenotype and in older mice there are compensatory changes in 







necrosis within the cortex and extending into the medulla (Figure 4.7 B). 
At 200X the tubular outlines are apparent, but within the tubules there 
is complete necrosis of tubular epithelial cells (Figure 4.7A). There is a 
sharp demarcation between the necrotic and viable areas of the kidney 
with several congested vessels and a cellular infiltrate with a densely 
cellular interstitium at this junction consisting of proliferative fibroblasts 
and infiltrating lymphocytes, plasma cells, macrophages, and 
neutrophils. However, some Gpr41 KO kidneys demonstrated no obvious 
lesions. Glomeruli in Gpr41 KO kidneys appear slightly shrunken 
compared to Gpr41 WT glomeruli.  
 
 
A: 200X magnification 
 




Figure 4.7: H&E stained sections of some Gpr41 KO kidney sections 
demonstrated moderate nephritis. 
 
Gpr41 KO mice exhibit isolated systolic hypertension 
At 3 months of age, male Gpr41 KO mice exhibited isolated systolic 
hypertension at baseline (Figure 4.8) both during the day and night. The 
reported values (Fig. 4.8) represent averages from a 5 – day recording of 
BP in 3-month-old male animals of both genotypes. Consistent with 
higher systolic pressures in the Gpr41 KO animals, the pulse pressures 
of Gpr41KO were significantly elevated during both dark and light cycles 
(Figure 4.9). The mean arterial pressure, diastolic pressure, and heart 
rate were similar between the two genotypes (Figure 4.8, 4.9). However, 
dP/dt (a measure of LV contractility) was elevated in the Gpr41-/- mice, 
which alludes to a lower compliance of blood vessels and increased 







Isolated systolic hypertension is associated with a two- to five-fold 
increase in mortality due to cardiovascular complications. Isolated 
systolic hypertension is most commonly attributed to large inelastic 
arteries and aortic insufficiency. It is also presumed that systolic 
hypertension arises with aging as a result of inelastic rigid arteries. In 
older populations, systolic hypertension is related to hypertensive cardiac 
failure, stroke and coronary heart disease[112, 116, 124, 125].  
 
Now, with the evidence that Gpr41 KO mice exhibit isolated systolic 
hypertension, the first parameter to assess to determine causality was 
large vessel stiffness. Two approaches were used to assess blood vessel 
stiffness in the Gpr41 KO and Gpr41 WT mice, pulse wave velocity to 
assess vessel stiffness in vivo and tensile testing of aortas to assess blood 
vessel stiffness ex vivo[121, 126].  
 
In order to assess blood vessel stiffness in vivo, we measured pulse wave 
velocity in Gpr41 KO and Gpr41 WT animals. Pulse wave velocity (PWV) 
is a measure of arterial stiffness, the rate at which pressure waves move 
down the blood vessels. PWV is a highly reliable prognostic parameter for 
cardiovascular morbidity and mortality in patients with end-stage renal 





In a cardiac cycle, blood moves out of the left ventricle, into the aorta and 
subsequently through the vessels of the circulatory system. Left 
ventricular contraction during systole to eject blood into the ascending 
aorta acutely dilates the aortic wall and generates a pressure wave that 
moves along the aorta and its branches. The velocity of the pressure 
wave gives a measure of arterial compliance. Changes in the arterial wall 
as a result of aging or other causes, result in stiffer vessels and under 
these circumstances, the velocity of the pressure wave is increased. 
Pressure waves generated constantly due to cardiac function traverse 
through the arteries and are also reflected back at the end of systole. 
When the pressure waves move faster under inelastic conditions of the 
aorta, the reflected waves move back quicker too, causing an increased 
afterload on the ventricle, resulting in a greater systolic pressure 
requirement to overcome this afterload[115, 116, 124, 125]. PWV is 
collected by using two pressure catheters placed a known distance (pulse 
wave distance) from each another.  The time taken by the pressure wave 
to go from the upstream pressure catheter to the downstream pressure 
catheter is the Pulse Transit Time (PTT). PWV is then calculated by 
dividing the distance by the transit time.  
 
In a cohort of age - matched Gpr41 KO and Gpr41 WT mice at 3 months 
of age, there was no observed difference in the PWV. However, at 6 





cause the increased PWV observed in older Gpr41 KO mice. Tensile 
properties of aortas from Gpr41 KO and Gpr41 WT mice was examined 
by applying varying amounts of strain on the blood vessel followed by 
measurement of stress developed. Tensile properties of intact aortas was 
assayed and a subset of aortas were decellularized to measure tensile 
properties of the aortic media in the absence of cells. Surprisingly, intact 
aortas from Gpr41 KO and Gpr41 WT animals do not show any 
differences in their tensile properties, while decellularized Gpr41 KO 
aortas have increased compliance (Figure 4.12). This result rules out the 
possibility of changes in extracellular matrix in the aortic media or 
elastin fracture as a potential cause of increased PWV. On the other 
hand, the inherent cause of systolic hypertension and increased PWV in 
older animals could stem from impaired signaling in the endothelium 





Figure 5.7: Blood vessel tensile properties are similar in intact aorta from 
Gpr41 KO and Gpr41 WT mice, decellularized aorta from Gpr41 KO mice 
are more significantly compliant, p<0.0001 
 
Chronic sodium propionate administration doesn’t elicit a blood 
pressure response in Gpr41 KO mice 
200mM SCFA treatment in drinking water has previously been shown to 
be sufficient to activate SCFA receptors in mice. However, contrary to our 
hypothesis, we found that neither sodium propionate nor sodium 
chloride treatment significantly altered systolic, mean, or diastolic BP 
(Figure 4.13, 4.14), systolic hypertension in Gpr41 KO mice was observed 
throughout the experimental duration (Figure 4.13). Pulse pressure was 
consistently higher in Gpr41 KO mice throughout the experiment (Figure 
4.14), although a minor decrease in heart rate was observed upon 
propionate treatment in Gpr41 KO (Figure 4.15).  
 
Since we observed a blood pressure response in WT and Gpr41 KO mice 
upon acute SCFA administration, but didn’t observe any stable effects of 
chronic SCFA delivery on BP, it could be possible that SCFA – induced 
blood pressure changes are transient and become negligible in the 






Table 4.2 Plasma electrolytes during baseline, sodium propionate and sodium chloride treatments 
Baseline Propionate NaCl 
WT KO WT KO WT KO 
mmol / L Na 146.71 148.10 150.75 151.60 148.75 147.60 
K 6.01 6.22 6.00 6.06 6.10 5.96 
Cl 116.86 118.60 114.50 112.80 112.00 113.60 
iCa 1.14 1.17 1.22 1.28 1.25 1.27 
TCO2 15.29 15.00 20.75 18.40 24.25 21.00 
mg/dL Glucose 205.43 184.70 187.00 199.60 206.50 245.40 
BUN 18.57 20.00 20.25 21.00 16.75 19.60 
creatinine <0.2 <0.2 <0.2 <0.2 0.20 0.20 
% PCV hematocrit 46.00 41.35 48.00 48.00 46.75 45.40 
g/dL hemoglobin 15.63 15.60 16.33 16.32 15.88 15.44 
mmol/L AnGap 21.43 21.70 22.50 27.20 19.25 19.80 
Plasma samples collected for analysis of electrolytes during chronic sodium propionate treatment 
exhibited mild hemolysis, hence elevated potassium values 
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Cl 116.86 118.60 114.50 112.80 112.00 113.60 
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TCO2 15.29 15.00 20.75 18.40 24.25 21.00 
mg/dL Glucose 205.43 184.70 187.00 199.60 206.50 245.40 
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Heart rate doesn’t differ significantly between Gpr41 KO and Gpr41 WT 
mice at baseline or during the high salt or low salt diets. There is a minor 
increase in heart rate observed in both genotypes immediately after 
switching to a new diet (Figure 4.19).  
 
4.5 Discussion 
Characterization of various physiological parameters in Gpr41 KO and 
WT mice revealed that 
(i) Plasma renin concentration was not different between Gpr41 KO and 
Gpr41 WT animals (both male and female). Olfr78 is expressed in 
renal afferent arteries and stimulates renin secretion. 
(ii) Plasma electrolytes are similar in 3-month-old Gpr41 KO and WT 
males and females. This indicates that on a large-scale level, ion 
balance in plasma is not perturbed in Gpr41 KO mice.  
(iii) Histological analysis of Gpr41 KO kidneys shows an apparent trend 
in decrease of glomerular size.  
(iv) Gpr41 KO mice are hypertensive at 3 months of age; they exhibit 
isolated systolic hypertension, elevated pulse pressure with no 
significant difference in diastolic pressure and heart rate compared to 
Gpr41 WT mice. 
(v) Analysis of vascular properties of Gpr41 KO and WT mice revealed 




velocity. On the other hand, isolated aortas do not exhibit any 
changes in their tensile properties. 
 
Isolated systolic hypertension in Gpr41 KO mice 
Usually hypertension is characterized by an increase in both systolic 
pressure and diastolic pressure. Increased systolic pressure alone in 
Gpr41 KO mice indicates that they have isolated systolic hypertension, 
which could be a result of stiff, less compliant blood vessels, resulting in 
an increase of afterload. This coupled with an increase in dP/dt indicates 
that there impaired relaxation of blood vessels in Gpr41 KO requiring a 
greater systolic pressure to pump blood into the aorta. Since Gpr41 is 
expressed in the endothelium, which modulates smooth muscle stiffness 
by secreting various factors, it is possible that Gpr41 acts on a key 
pathway in the endothelium to mediate vasodilation.  
 
Hypertension in Gpr41 KO mice is vascular in nature 
Multiple lines of evidence indicate that the hypertension observed in 
Gpr41 KO is vascular in nature.  First, similar plasma renin is similar in 
Gpr41 KO and WT mice. Similar plasma renin concentration in Gpr41 
KO and WT mice indicates that the cause of hypertension is possibly 
vascular. A second line of evidence that the hypertension is likely 




form of hypertension. A third line of evidence that the hypertension is 
vascular is the fact that it is not salt-sensitive in Gpr41 KO mice. 
 
It is very intriguing that 3-month-old Gpr41 KO mice, which exhibit 
isolated systolic hypertension, do not have increased pulse wave velocity 
(PWV). 6-month-old Gpr41 KO mice have higher PWV, indicating that the 
compliance of Gpr41 KO blood vessels decreases faster with aging. This 
could indicate that increased systolic pressures exacerbate the age – 
associated decrease in blood vessel compliance, causing a decrease of the 
compliance of blood vessels in Gpr41 KO mice. If absence of Gpr41 in 
blood vessels increases age associated decrease in blood vessel 
compliance, Gpr41 could be an ideal target for treating resistant 
hypertension with hardening of the arteries that greatly decrease 
compliance.  
 
Tensile testing of blood vessels to correlate the increased pulse wave 
velocity to possibly stiffer aortas showed no differences in tensile 
properties in intact vessels and increased compliance in decellularized 
aortas. Based on this evidence, it is possible that increased vascular tone 
or impaired signaling in the endothelium of Gpr41 KO mice could 
contribute to the development of isolated systolic hypertension. This line 
of evidence also rules out the possibility of increased collaged deposition 




It was observed that Gpr41 KO mice do not exhibit salt sensitive 
hypertension. All the evidence accumulated till this point indicates that 
hypertension in Gpr41 KO mice is vascular in nature with minimal 
hormonal and renal components. Absence of a BP response to a high salt 
diet confirms the fact that Gpr41 KO mice have vascular dysfunction, 
leading to hypertension. Renal salt handling appears to be normal and 
able to compensate for a higher salt load in Gpr41 KO and WT mice.  
 
Olfr78 mediates hypertension via an increase in plasma renin 
concentration, since SCFAs stimulate renin secretion from the 
juxtaglomerular apparatus in an Olfr78-dependent manner. Olfr78-
induced hypertension is primarily hormonal (renin), whereas Gpr41-
mediated hypertension seems to be primarily vascular in nature. This 
shows that even though Gpr41 and Olfr78 are activated by the same 
ligands and alter cellular cAMP in opposing directions upon activation; 
signal via strikingly different and unique mechanisms. This gives two 
novel BP regulation pathways that can be targeted by small molecule 
drugs or by dietary alterations to modulate BP in hypertension.  
 
Vascular effects of SCFA – transient in nature? 
Previously, Gpr41 KO and WT mice showed different responses to acute 
SCFA doses, while wild-type (WT, C57BL/6) mice exhibited a hypotensive 




would increase BP in Gpr41 KO mice because Olfr78, which opposes the 
effect of Gpr41 acts unopposed in the KO mice, which lack Gpr41. An 
increase, if observed would have shed light on the mechanism of BP 
regulation involving Gpr41, under chronic exposure to SCFAs.  
 
200mM sodium propionate delivered chronically to Gpr41 KO and WT 
mice in the drinking water did not have a lasting effect on blood pressure 
in Gpr41 KO and Gpr41 WT mice. This highlights the transient nature of 
BP response to SCFAs. Even in the acute dose response experiments, BP 
exhibited a step decrease and recovered in a period of 10 minutes. Since 
during analysis, we take into account the average systolic and diastolic 
BP values during the entire treatment period, we may not be observing 
transient changes in BP due to SCFA consumption. Furthermore, since 
200mM propionate is delivered via drinking water ad libitum, there is no 
steady dosing of propionate and it is hard to assign minor variations in 
BP to propionate consumption. In fact, we observe a minor non-
significant increase in systolic BP in both genotypes during sodium 
propionate and sodium chloride administration. Since Gpr41-mediated 
changes in BP are mainly vascular, it is a possibility that they are also 
transient and short-lived. On the other hand Olfr78 mediates an increase 
in plasma renin concentration, which would result in a sustained 
increase in BP over a longer period. This increase in plasma renin could 




Another plausible reason for the absence of a BP response to chronic 
SCFA treatment could be the inability of oral SCFA delivery to 
significantly increase plasma SCFA levels due to rapid uptake by tissues 
and small volume ingested. If this were the case, sustained delivery 
needs to be used as an alternative to oral delivery to study the BP effects 
of chronic SCFA delivery. 
 
Renal histology and morphology 
Although a majority of this study was concerned with the role of Gpr41 
in blood vessels and its downstream signaling in the endothelium, 
localization of Gpr41 in the renal glomerulus is equally important and 
crucial for blood pressure regulation. The trend of Gpr41 KO glomeruli to 
be smaller is consistent with the localization of Gpr41 in glomeruli and 
indicates that Gpr41 could possibly play a role development of proper 
structure and size of the glomerulus. This phenotype requires further 
investigation of renal parameters and glomerular filtration rate to 








5 Signaling mechanisms of SCFAs in blood vessels 
 
5.1 Abstract 
Previous studies have found that SCFAs dilate blood vessels ex vivo. 
Using microvascular chambers to test vascular responses of tail arteries, 
we confirmed that both acetate and propionate dilate resistance vessels 
in a dose-dependent manner. This confirms previous reports that SCFAs 
dilate blood vessels and that Gpr41 could play a role in regulating 
vascular tone upon activation. We also found that SCFA-mediated 
vasodilation is dependent on the endothelium - consistent with a role for 
endothelial Gpr41 in mediating this response. In our attempts to narrow 
down the pathway of SCFA – mediated vasodilation, we blocked eNOS 
with L-NAME and saw that inhibition of eNOS doesn’t inhibit SCFA-
mediated vasodilation. SCFA-mediated vasodilation of tail arteries is 






We have previously showed that SCFAs decrease BP via Gpr41. Other 
groups have showed that SCFAs dilate blood vessels ex vivo. SCFAs 
decrease BP by mediating vasodilation. Given that there are two SCFA 
receptors, Gpr41 in the endothelium and Olfr78 in vascular smooth 
muscle cells, it is important to decipher which component of blood 
vessels mediates the hypotensive response in order to further 
understand underlying signaling pathways and to use key players in the 
pathway as potential pharmacological targets to treat hypertension.  
 
In this section, we analyzed vascular responses of tail arteries to SCFAs 
and isolated the component of blood vessels that mediates this response 
by comparing vascular responses of intact blood vessels and denuded 
vessels lacking functional endothelial cells. Since Gpr41 mediates a 
hypotensive response, we hypothesize that the endothelial layer would 
mediate SCFA-dependent vasodilation. We also attempted to identify the 
molecular mechanisms by which SCFAs signal beginning with eNOS, 
since it is an important pathway by which vasodilation is mediated and 






5.3 Materials and methods 
 
Ex-vivo vascular relaxation experiments 
3-month-old male mice (Gpr41 WT and KO) were euthanized by CO2 
asphyxiation. Proximal segments of the tail artery were dissected rapidly 
and placed in cold Krebs-Ringer bicarbonate solution containing 
118.3mM NaCl, 4.7mM KCl, 1.2mM MgSO4, 1.2mM KH2PO4, 2.5mM 
CaCl2, 25.0mM NaHCO3, and 11.1mM glucose (control solution). The tail 
arteries (either intact or with endothelium denuded) were cannulated at 
both ends with glass micropipettes, secured using 12-0 nylon 
monofilament suture, and placed in a microvascular chamber (Living 
Systems, Burlington, VT)[122, 123]. The arteries were maintained at a 
constant transmural pressure (PTM) of 60 mmHg in the absence of flow. 
The chamber was superfused with control solution, maintained at 37°C, 
pH 7.4, and gassed with 16% O2-5% CO2-balance N2. The chamber was 
placed on the stage of an inverted microscope (20X; Nikon TMS-F) 
connected to a video camera (CCTV camera; Panasonic). The vessel image 
was projected on a video monitor, and the internal diameter was 
continuously determined by a video dimension analyzer (Living Systems 
Instrumentation) and was monitored using a BIOPAC (Santa Barbara, 
CA) data acquisition system[122, 123]. The tail vessels were allowed to 
equilibrate at PTM of 60mmHg for 30 minutes. After equilibration, the 




sodium acetate in the superfusate and the internal diameter of the 
vessels were recorded over time. After propionate treatment, the 
reactivity of the vessels (and presence/absence of endothelium) was 
confirmed by acetylcholine.  
 
5.4 Results 
Acute SCFAs mediate a hypotensive response via vasodilation. Human 
colonic arteries have been reported to exhibit vasodilation upon exposure 
to SCFAs[104]. The hypotensive response to SCFAs is primarily mediated 
by Gpr41, but is opposed by Olfr78[26]. In order to investigate the 
molecular mechanism and signaling events driven by SCFAs to mediate 
vasodilation, vascular responses of resistance arteries were examined 
upon addition of SCFAs in a vascular chamber (Figure 5.1, A)[123, 126-
128]. Isolated resistance vessel from the tail exhibited vasodilation upon 
addition of increasing amounts of sodium propionate (Figure 5.1, B), 
indicating that this setup could be used to study downstream signaling 
events involved in this pathway.  
 
Gpr41 is localized in the vascular endothelium and it has been 
established that Gpr41 acts to decrease blood pressure, based on acute 
dose responses[5, 26] and systolic hypertension observed in Gpr41 KO 
mice. Hence, it is possible that SCFA – mediated vasodilation observed is 





similar to the hypotensive response in vivo[26]. This SCFA – mediated 
vasodilation, was endothelium – dependent (Figure 5.2, 5.3), consistent 
with the localization of Gpr41. Intact arteries exhibit vasodilation in a 
dose – dependent manner upon SCFA treatment, the vasodilation was 
severely attenuated in the denuded arteries lacking functional 
endothelium.  
 







(iii) endothelial – derived hyperpolarizing factor (EDHF) 
Since the nature of hypotensive response to acute SCFA treatment in 
vivo is rapid and endothelium – dependent, it is possible that Gpr41 may 
induce vasodilation via eNOS; since nitric oxide mediated vasodilation is 
would match the timescale of responses observed.  
 
SCFAs mediate vasodilation in an eNOS independent manner 
The next set of vascular chamber experiments were performed with SCFA 
(to mediate vasodilation) and L-NAME, a pharmacological inhibitor of 
eNOS to determine if the response was eNOS dependent. However, SCFA 
mediated vasodilation was not inhibited in the presence of L-NAME, 
indicating that SCFA-mediated vasodilation is mediated predominantly 
by an eNOS-independent mechanism (Figure 5.4, 5.5). 
 
 
Figure 5.4: L-NAME doesn’t significantly inhibit SCFA – induced 






The mechanism of SCFA–mediated vasodilation was investigated and it 
was observed that  
(i) A functional endothelium is crucial for SCFA – mediated vasodilation 
in tail arteries. Denuded vessels lacking a functional endothelium do 
not vasodilate upon treatment with acetate and propionate.  
(ii) Inhibition of eNOS with L-NAME does not inhibit vasodilation of tail 
arteries upon SCFA treatment. The time scale of vasodilation seen 
with SCFAs and rapid recovery seen in vivo seemed to fit with role for 
eNOS in the response. Surprisingly, since L-NAME did not inhibit the 
vasodilation seen in tail arteries, it could be mediated by 
prostacyclins or EDHF. Further experiments are required to decipher 
the exact pathway.  
 
Endothelium-dependent SCFA mediated vasodilation: A role for 
Gpr41? 
It has been shown previously that SCFAs mediate vasodilation. Our 
results confirm the observation and prove that the decrease in BP 
observed upon acute SCFA delivery is possibly via vasodilation. This is 
interesting because Gpr41 and Olfr78, the two major players in SCFA-
mediated BP regulation are expressed in blood vessels, but Olfr78 is 
expressed in vascular smooth muscle cells and Gpr41 is expressed in the 




effects on BP are very different, even though they are localized to 
neighboring cell types in a blood vessel. Our observation that a 
functional endothelium is absolutely essential to mediate SCFA-
dependent vasodilation is novel and consistent with our earlier finding of 
Gpr41 in the endothelium. This supports the hypothesis that Gpr41 
mediates a hypotensive response, since Gpr41 is localized to the vascular 
endothelium. Gpr41 signals via the inhibitory G protein, Gi, which plays 
a major role in vasodilation events mediated by the endothelium. Further 
experiments with Gpr41 antagonists and vessels from Gpr41 KO mice 
are required to validate the role of Gpr41 in this pathway.  
 
SCFA and vasodilation: role for eNOS? 
Initially, it was assumed that eNOS might mediate SCFA-dependent 
vasodilation, since the time frame of both the in vivo BP response and ex 
vivo vasodilation are very rapid and in vivo BP recovers quickly too. Our 
attempts to monitor vasodilation in the presence of L-NAME, an eNOS 
inhibitor showed that SCFA-mediated vasodilation could occur even 
when eNOS was inhibited. This shows that SCFAs signal possibly via 
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